The relationship between serum tumor-associated trypsin inhibitor levels and clinicopathological parameters in patients with gastric cancer
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, cilt.17, sa.21, ss.2923-2928, 2013 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 17 Sayı: 21
- Basım Tarihi: 2013
- Dergi Adı: EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.2923-2928
- Anahtar Kelimeler: Tumor-associated trypsin inhibitor, Clinical-pathological features, Gastric cancer, COLON-CANCER, EXPRESSION, TATI, FIBROBLASTS, ANTIGEN, URINE
- Bursa Uludağ Üniversitesi Adresli: Hayır
Özet
BACKGROUND: Tumor-associated trypsin inhibitor (TATI) is expressed with trypsinogen in tumors. We studied the clinical-pathologic association and significance of preoperative serum levels of TATI in gastric cancer patients. PATIENTS AND METHODS: Pre-treatment serum levels of TATI in patients with gastric cancer and healthy controls were analyzed by a specific enzyme-linked immunosorbent assay (ELISA). RESULTS: Statistically significant differences were found in serum TATI levels between patients with gastric cancer and healthy controls (p < 0.0001). There was a significant relationship between the serum levels of TATI and clinicopathological parameters. However, serum levels of TATI were significantly higher in patients with an advanced T stage (T3) (p < 0.001), lymph node metastasis (p < 0.001) and an advanced TNM stage (stage III or IV; p < 0.001). CONCLUSIONS: Our study suggests that TATI may be used to identify potentially high-risk groups of upper gastric carcinoma. Elevated level of TATI was associated with progressive disease or advanced stage.